基于GEO数据库的阿尔茨海默病生物标志物的探索和验证
Yansha Gan1, Jiaojiao Sun1, Danting Yang1
1The Affiliated Mental Health Center of Jiangnan University, Wuxi Central Rehabilitation Hospital, Wuxi, Jiangsu 214151, China.
IBRO neuroscience reports
|January 28, 2026
概括
这项研究使用生物信息学识别了阿尔茨海默病 (AD) 中的关键基因. 基因RBL2显示了与AD风险的因果关系,表明其作为早期诊断生物标志物的潜力.
科学领域:
- 基因组学和生物信息学
- 神经科学是一个神经科学.
- 生物标志物发现发现
背景情况:
- 阿尔茨海默病 (AD) 对早期诊断和治疗构成了重大挑战.
- 识别新的遗传因素和生物标志物对于推动AD研究至关重要.
- 生物信息学方法为分析复杂的基因组数据集提供了强大的工具.
研究的目的:
- 在阿尔茨海默病 (AD) 中使用生物信息学识别差异表达的基因.
- 探索潜在的生物标志物用于早期诊断AD.
- 为阿尔茨海默病的早期诊断和治疗策略提供新的见解.
主要方法:
- 来自基因表达综合 (GEO) 数据库的两个AD相关数据集 (GSE66351,GSE153712) 的分析.
- 不同甲基化分析,LASSO回归,皮尔森相关性和蛋白质与蛋白质相互作用 (PPI) 网络分析.
- 基因和基因组的京都百科全书 (KEGG) 和基因本体学 (GO) 丰富分析,其次是门德尔随机化.
主要成果:
- 确定了387个重叠的差异甲基化位点,映射到297个基因.
- GO和KEGG的分析强调了其参与信号传导,细胞循环调节和PI3K-Akt/TGF-β通路.
- 确定了五个关键基因 (EBF1,IGF1,EGR2,PRDM16,RBL2),其中RBL2显示出与AD风险的统计学上显著的因果关系 (OR=1.201,p=0.000249).
结论:
- 证实了已知的AD相关基因,并揭示了RBL2和AD之间的显著潜在联系.
- 确定了RBL2基因与AD发病风险之间的验证因果关系.
- RBL2成为阿尔茨海默病早期诊断的有希望的生物标志物候选者.
相关概念视频
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...